The desirability and feasibility of economic studies of drugs post-launch

European Journal of Health Economics

Volumn 7, Issue 1, 2006, Pages 5-6

  Drummond, Michael ^a,b   Mason, Anne ^a   Towse , Adrian ^b  

^a Office of Health Economics   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG RESEARCH; EDITORIAL; PRIORITY JOURNAL; REIMBURSEMENT;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMETRIC;

EID: 33644860468     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0337-2     Document Type: Editorial

References (2)

1. Claxton K (1999) Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8:269-274
2. Mason A, Drummond MF, Towse A (2006) Economic post-launch studies: matching the desirable with the feasible. OHE monograph. Office of Health Economics: London (http://www.ohe.org)